Develops cell replacement therapies for patients with serious conditions, including retinal disease, spinal cord injury and hearing loss.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases…View ↗
The cells we have or may seek to manufacture are intended to replace the same type of cells that the patient has lost, or which have become…View ↗
OPC1, an allogeneic oligodendrocyte progenitor cell therapy currently in Phase 1/2a development for the treatment of spinal cord injuries…View ↗
ReSonanceTM (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy currently in preclinical development under…View ↗
Lineage gets upfront license fees and milestone payments from collaborators, and is paid for research work as it progresses. It also earns royalties and service revenue under royalty and service agreements.
10-K for FY2025, filed Mar 5, 2026Roche Agreement - From the inception of the December 2021 Roche Agreement through the quarter ending September 30, 2025 the total…View ↗
In the fourth quarter of 2025, the achievement of the first milestone under the agreement in the amount of $5.0 million resulted in a…View ↗
WDI Agreement - In August 2025, the Company entered into a multi-year, multi-phase research collaboration agreement (the RCA) with WDI.…View ↗
Revenues from royalties, licenses and service agreements are recognized as revenue in the period earned and are generated from royalty and…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$14.6M
10-K for FY2025, filed Mar 5, 2026
$14.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaboration Revenues
Mix
10-K for FY2025, filed Mar 5, 2026 |
93%
FY2022: 91%
|
Collaboration Revenues, FY2025
$13.6M Sources
|
Mix |
|
Royalties, License and Other Revenues
Licensed
|
6.5%
FY2022: 9.1%
|
Royalties, License and Other Revenues, FY2025
$947K Sources
|
Licensed |
Partners collaborate directly with Lineage on cell-development programs, including Roche for OpRegen and WDI for ReSonance.
10-K for FY2025, filed Mar 5, 2026
No. It lost $63.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
$4.2MView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
In connection with the Acquisition, NeuroAirmid entered into an Amended and Restated Exclusive License Agreement, effective November 12…View ↗
Growing. Revenue grew 3.4x in 4 years, from $4.3M in FY2021 to $14.6M in FY2025, about 35% a year.
Pipeline focus
The older report included a dendritic-cell cancer immunotherapy program; the latest overview instead describes cell replacement programs for retinal disease, spinal cord injury and hearing loss.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 5, 2026VAC, an allogeneic cancer immunotherapy comprised of antigen-presenting dendritic cells. One of the VAC product candidates, VAC2, is…View ↗
We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. Certain diseases…View ↗
OPC1, an allogeneic oligodendrocyte progenitor cell therapy currently in Phase 1/2a development for the treatment of spinal cord injuries…View ↗
ReSonanceTM (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy currently in preclinical development under…View ↗
Competes with Abbvie, Century Therapeutics, Bayer, Regeneron Pharmaceuticals, Santen Pharmaceuticals, Sana Biotechnology, jCyte, Astellas Pharma, and Apellis Pharmaceuticals
10-K for FY2025, filed Mar 5, 2026As mentioned above, some of our competitors have substantially greater financial and other resources than we have, such as larger research…View ↗
Loading...